Mr Vickery has over 25 years' experience as a finance professional, with a particular focus on life sciences and innovation-based businesses. As Chief Financial Officer (CFO) of Viralytics, he was a key member of the team that accomplished the A$502 million acquisition by Merck in June 2018. For three years he was CFO of Clarity Pharmaceuticals Ltd, including through its successful 2021 ASX IPO. In these roles Mr Vickery has led several major corporate transactions and re-engineered key functions, including financial reporting, IT, governance, HR and insurance.

He has previously held senior roles with several other listed and unlisted biotech and innovation-based businesses. Early in his career he served in the Chartered Accounting profession before transitioning to a corporate role at Swire Group acting across a range of treasury, taxation and company secretarial functions. Mr Vickery is an Associate of the Institute of Chartered Accountants and the Governance Institute of Australia.